Blueprint Medicines, a precision therapy company, completed the acquisition of Lengo Therapeutics, a privately held precision oncology company, for $465m. "The acquisition of Lengo Therapeutics and its lead candidate LNG-451 enables Blueprint Medicines to expand our pipeline in lung cancer and harness our experience and expertise to advance precision oncology therapies for the patients who need them. I want to thank the Lengo Therapeutics team, again for their work to advance the highly selective therapeutic candidate LNG-451, but also for completing the IND submission with a continued sense of urgency. Pending FDA clearance of the application, we plan to advance LNG-451 into the clinic in the first quarter of 2022," Fouad Namouni, Blueprint Medicines President of Research & Development.